Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $65.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 52.19% from the company’s current […]
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $30.91 and last traded at $31.13, with a volume of 353275 shares. The stock had previously closed at $32.95. Analyst Ratings Changes A number of equities analysts have recently weighed in on XENE […]
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price […]
Candriam S.C.A. trimmed its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 2.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 719,206 shares of the biopharmaceutical company’s stock after selling 16,678 shares during the quarter. Candriam S.C.A. owned 1.14% of Xenon […]
Cantor Fitzgerald reissued their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $58.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com initiated coverage on Xenon Pharmaceuticals in […]